National Medical Cyclotron to retire

The facility produced medical isotopes for application in nuclear medicine.
 
The NMC produced about 2 million patient doses in its twenty years of service providing cyclotron-based products across Australia and to nearby countries. 
 
The key isotopes currently produced at the NMC are Thallium-201, Gallium-67 and Iodine-123. Arrangements are in place to import these until a new capability is established in Australia. 
 
The 15 employees affected are to be redeployed at the Lucas Heights’ campus, subject to final agreements being reached.
 
ANSTO provides around 500,000 patient doses of reactor-produced medical isotopes per year from the OPAL reactor which are neutron “rich”. The 100,000 doses of cyclotron-produced isotopes from the NMC are “proton rich” and cannot be made in a reactor. 
Published: 07/10/2009

Recent articles

See all »

Media enquiry form

If you have a media enquiry please call
Phil McCall: +61 438 619 987

Or

Send »

Please provide us with your name, phone number and
email so we can get back to you.

Error: Enquiry was not sent! Check all fields have been populated correctly.
Success: Enquiry was sent successfully.